Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2024 Rev YoY: +6.0% EPS YoY: +1,557.1% Move: +0.50%

Walgreens Boots Alliance

WBA

$11.98 0.50%

Exchange NASDAQ Sector Healthcare Industry Medical Pharmaceuticals

Q4 2024

Published: Oct 15, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for WBA

Reported

Report Date

Oct 15, 2024

Quarter Q4 2024

Revenue

37.55B

YoY: +6.0%

EPS

-3.48

YoY: +1,557.1%

Market Move

+0.50%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $37.55B up 6% year-over-year
EPS of $-3.48 increased by 1% from previous year
Gross margin of 16.7%
Net income of -3.01B
""We are reorienting to our legacy strength as a retail pharmacy-led company which will enable us to respond to shifts in consumer behavior dynamically." - Tim Wentworth, CEO" - Tim Wentworth

WBA

Walgreens Boots Alliance Inc

Period Q4 2024

Currency USD

Report Type Quarterly Earnings

Generated Feb 12, 2026

Executive Summary

Walgreens Boots Alliance Inc (WBA) reported disappointing results for Q4 2024, with a net loss of $3.0 billion, driven by significant charges pertaining to valuation allowances on deferred tax assets and goodwill impairments. Despite a positive revenue increase of 6.00% year-over-year to $37.5 billion, demand pressures, particularly in retail segments, coupled with ongoing reimbursement issues in the pharmacy business, highlight the challenges the company faces. Management has outlined a clear strategy focusing on transforming the business into a pharmacy-led health and beauty retail company, with ambitions for operational efficiency and debt reduction that should resonate with investors in the long term.

Key Performance Indicators

Revenue

Increasing

37.55B

QoQ: 3.29% | YoY: 6.00%

Gross Profit

Decreasing

6.25B

16.65% margin

QoQ: -3.19% | YoY: -3.43%

Operating Income

Increasing

-977.00M

QoQ: -980.18% | YoY: 116.63%

Net Income

Increasing

-3.01B

QoQ: -973.55% | YoY: 1 569.44%

EPS

Increasing

-3.48

QoQ: -970.00% | YoY: 1 557.14%

Revenue Trend

Margin Analysis

Financial Highlights

1. Revenue Growth: Revenue for Q4 2024 reached $37.5 billion, up 6.00% YoY and 3.29% QoQ.
2. Net Income: Adjusted net income was a loss of $3.0 billion compared to a loss of $3.1 billion in the previous year.
3. Earnings Per Share (EPS): Reported EPS was -$3.48, a significant decline in performance due to non-recurring charges.
4. Cash Flow: Operating cash flow for the fiscal year totaled $1 billion, positively impacted by working capital initiatives. Free cash flow increased to $1.1 billion for the quarter, reflecting substantial operational cash management.
5. Balance Sheet: The company reduced net debt by $1.9 billion, closing the fiscal year with $3.2 billion in cash and equivalents and $5.8 billion credit facilities available.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	37.55B	6.00%	3.29%
Gross Profit	6.25B	-3.43%	-3.19%
Operating Income	-977.00M	116.63%	-980.18%
Net Income	-3.01B	1 569.44%	-973.55%
EPS	-3.48	1 557.14%	-970.00%

Key Financial Ratios

Gross Profit Margin

Weak

16.70%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-0.03%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-0.08%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.04%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.29%

Return on equity suggests inefficient capital allocation

Current Ratio

Concern

0.68

Current ratio below safe levels, potential liquidity risk

Debt to Equity

High Risk

3.15

Debt-to-equity indicates high leverage and elevated financial risk

P/E Ratio

Negative

-0.67x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.77x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2025	39,459.00	-0.31	+7.5%	View
Q4 2024	37,547.00	-3.48	+6.0%	View
Q3 2024	36,351.00	0.40	+2.6%	View
Q2 2024	37,052.00	-6.85	+6.3%	View
Q1 2024	36,707.00	-0.08	+10.0%	View

WBA

Walgreens Boots Alliance

Q1 2025 Report

Walgreens Boots Alliance Inc (WBA) Q1 2025 Financial Results Report: Navigating Challenges Amid Strategic Optimizations...

Read full report

WBA

Walgreens Boots Alliance

Q3 2024 Report

Walgreens Boots Alliance Inc (WBA) Q3 2024 Financial Results Report: A Navigational Update in a Challenging Environment...

Read full report

WBA

Walgreens Boots Alliance

Q2 2024 Report

Walgreens Boots Alliance Inc (WBA) Q2 2024 Financial Results: Navigating Challenges with Strategic Depth...

Read full report

WBA

Walgreens Boots Alliance

Q1 2024 Report

Walgreens Boots Alliance Inc (WBA) Q1 2024 Financial Results: Navigating Challenges and Embracing Opportunities...

Read full report

Walgreens Boots Alliance (WBA) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More WBA Quarterly Reports

WBA

WBA

WBA

WBA

Q4 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

WBA Full Profile

WBA Financial Statements

Earnings Calendar